Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / KLK4

KLK4

Basics

Aliases:
This biomarker is also known as:
  • PSTS,
  • Kallikrein-like protein 1,
  • KLK-L1,
  • Enamel matrix serine proteinase 1,
  • Serine protease 17,
  • PRSS17,
  • Prostase,
  • hK4,
  • Human kallikrein 4,
  • Kallikrein-4,
  • EMSP1,

View in BioMuta

Description…

The glandular kallikreins are a distinct group of serine proteases with molecular masses of 25,000 to 40,000. Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. This gene is one of the fifteen kallikrein subfamily members located in a cluster on chromosome 19. Several human kallikrein genes have been isolated. hK4 is expressed in the prostate.

Attributes

QA State: Accepted
Type: Protein
Short Name:

Organs

The following organs have data associated with this biomarker…

Prostate

Attributes

Phase: One
QA State: Accepted

Overview

Kallikreins (KLKs) are highly conserved serine proteases that play key roles in a variety of physiological and pathological processes. KLK4 is regulated by androgens and is highly specific to prostate for expression. hK4 is intracellularly localized. KLK4 is predominantly expressed in the basal cells of the normal prostate gland and overexpressed in prostate cancer. hK4 has a unique structure and function compared with other members of the KLK family and may have a role in the biology and characterization of prostate cancer.

Performance Comment

hK2, hK4 and hK11 do not distinguish cases from controls in these populations.

Supporting Study Data

The following studies/protocols provide evidence supporting KLK4 indications for the Prostate…

Prostate Rapid Pre-Validation Set

Determine which markers move to validation using the prospectie prostate reference set samples.

View more about this study
Biomarker Characteristics Summary

No statistics found.

Decision Rule

No clinically useful decision rule found.

Additional Study-Specific Protocols
Study-Specific Publications

No study-specific publications defined.

Study-Specific Resources

No study-specific resources defined.

Prostate Rapid Reference Set Applicant: Diamandis - Mt Sinai (2006)

No abstract available.

View more about this study
Biomarker Characteristics Summary
Notes Sensitivity Specificity Prevalence NPV PPV Specific Assay Type
Measured among 123 samples (60 controls and 63 cases). Among the cases, 33 had low Gleason grade (<7) and 30 had high Gleason grade (>=7). When comparing cases with Gleason grade >=7 (n=30) to the pool of controls and cases with Gleason grade <7 (n=93), the AUC was 0.55 (0.45, 0.64). No specific cutoff was preselected for this analysis. N/A N/A N/A N/A N/A
Measured among 123 samples (60 controls and 63 cases). Among the cases, 33 had low Gleason grade (<7) and 30 had high Gleason grade (>=7). When comparing all cases (low and high Gleason grade) to controls, the AUC was 0.52 (0.44, 0.60). No specific cutoff was preselected for this analysis. N/A N/A N/A N/A N/A
Decision Rule

No clinically useful decision rule found.

Additional Study-Specific Protocols
Study-Specific Publications

No study-specific publications defined.

Study-Specific Resources

No study-specific resources defined.

Organ-Specific Protocols

No organ-specific protocols defined.

Organ-Specific Publications

No organ-specific publications defined.

Organ-Specific Resources

No organ-specific resources defined.

News

The final report of the 2013 Cancer Biomarkers Bioinformatics Workshop is now available.

Announcement 06/26/2014


Please click here to register for the 9th EDRN Scientific Workshop from September 8-10, 2014, in Bethesda, Maryland. The meeting registration page also has agendas and hotel reservation information.
Announcement 06/05/2014


Funding Opportunity Available

Both RFAs for Molecular and Cellular Characterization of Screen-Detected Lesions have been published.

RFA-CA-14-010.html

and

RFA-CA-14-011.html